genedrive Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Gino Miele

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.2yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Gino Miele (54 yo)

1.2yrs

Görev süresi

Dr. Gino Miele, PhD is Chief Executive Officer of genedrive plc from August 6, 2024. Dr. Miele is Chief Scientific Officer and Executive Director of genedrive plc from September 11, 2023. He has considerab...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Russell Shaw	CFO, Secretary & Director	no data	UK£158.08k	Veri yok
Gino Miele	CEO, Chief Scientific Officer & Executive Director	1.2yrs	Veri yok	0.20% € 28.9k
Ian Gilham	Independent Non-Executive Chairman	10yrs	UK£65.00k	0.30% € 43.7k
Chris Henry Yates	Independent Non-Executive Director	6.3yrs	UK£35.00k	0.049% € 7.2k
Thomas Lindsay	Independent Non-Executive Director	6.6yrs	UK£35.00k	0.17% € 25.1k

6.4yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: D6M 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

genedrive Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Genedrive plc Announces CEO Changes

genedrive plc, Annual General Meeting, Dec 29, 2023

genedrive plc Announces Chief Executive Officer Changes

genedrive plc, Annual General Meeting, Dec 29, 2022

High number of new directors

High number of new directors

Recent updates

genedrive plc to Report Fiscal Year 2024 Results on Nov 29, 2024

genedrive plc Announces Successful Funding Award to Its Clinical Partners from the National Institute for Health and Care Research in Collaboration with the UK Government Office for Life Sciences

New minor risk - Financial data availability

Genedrive plc Announces CEO Changes

Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug Administration

genedrive plc has completed a Follow-on Equity Offering in the amount of £6 million.

genedrive plc has filed a Follow-on Equity Offering in the amount of £3.5 million.

New major risk - Shareholder dilution

genedrive plc to Report First Half, 2024 Results on Mar 28, 2024

New major risk - Market cap size

genedrive plc, Annual General Meeting, Dec 29, 2023

Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022)

New major risk - Market cap size

genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023

New minor risk - Financial data availability

genedrive plc Announces Chief Executive Officer Changes

Genedrive plc Achieves UKCA Marking Registration for its New Genedrive CYP2C19 System

genedrive plc, Annual General Meeting, Dec 29, 2022

Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021)

genedrive plc to Report Fiscal Year 2022 Results on Nov 21, 2022

genedrive plc Files US FDA Pre-Submission for the Genedrive® MT-RNR1 Product Range

Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel Treatment

NICE to Evaluate the Genedrive MT-RNR1 Test

High number of new directors

Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory Agency

High number of new directors

Now 24% undervalued

First half 2022 earnings released

Genedrive plc Announces NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test

genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial Officer

Genedrive plc Provides Update on Point of Care Covid Test

genedrive plc to Report First Half, 2022 Results on Mar 29, 2022

genedrive plc Announces UK CTDA application for Point-of-Care Genedrive®?COV19-ID kit

Full year 2021 earnings released: UK£0.012 loss per share (vs UK£0.55 loss in FY 2020)

Insufficient new directors

Genedrive COVID-19 Point of Care device update

First half 2021 earnings released: EPS UK£0.019 (vs UK£0.089 loss in 1H 2020)

genedrive plc Enters Distribution Agreement with Mountain Horse Solutions

genedrive plc Provides an Update on its Antibiotic Induced Hearing Loss Assay

New 90-day high: €1.05

genedrive plc Enters into Distribution Agreement with Beckman Coulter Life Sciences

genedrive plc to Report First Half, 2021 Results on Mar 25, 2021

New 90-day low: €0.32

genedrive plc, Annual General Meeting, Dec 30, 2020

New 90-day low: €0.37

Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation Study

Revenue misses expectations

Full year 2020 earnings released: UK£0.55 loss per share

Genedrive Announces HCV ID Kit Demonstrates High Clinical Accuracy in India Study

Full year 2020 earnings released: UK£0.55 loss per share

Revenue misses expectations

New 90-day low: €0.71

genedrive plc to Report Fiscal Year 2020 Results on Nov 17, 2020

genedrive plc Announces South African Approval

genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNA

New 90-day high: €1.48

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş